146 related articles for article (PubMed ID: 22923024)
1. Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers.
Tello-Montoliu A; Rollini F; Desai B; Pasqualino G; Patel R; Sorensen AS; Sakariassen KS; Angiolillo DJ
J Thromb Thrombolysis; 2012 Oct; 34(3):297-9. PubMed ID: 22923024
[No Abstract] [Full Text] [Related]
2. Antiplatelet therapy: targeting the TxA2 pathway.
Fontana P; Zufferey A; Daali Y; Reny JL
J Cardiovasc Transl Res; 2014 Feb; 7(1):29-38. PubMed ID: 24353037
[TBL] [Abstract][Full Text] [Related]
3. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
4. From the design to the clinical application of thromboxane modulators.
Dogné JM; Hanson J; de Leval X; Pratico D; Pace-Asciak CR; Drion P; Pirotte B; Ruan KH
Curr Pharm Des; 2006; 12(8):903-23. PubMed ID: 16533159
[TBL] [Abstract][Full Text] [Related]
5. Platelet rich plasma transforms exogenous prostaglandin endoperoxide H2 into thromboxane A2.
Fitzpatrick FA; Gorman RR
Prostaglandins; 1977 Nov; 14(5):881-9. PubMed ID: 594390
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
Vezza R; Mezzasoma AM; Venditti G; Gresele P
Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
[TBL] [Abstract][Full Text] [Related]
7. Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation.
Richardson A; Sakariassen KS; Meyer JP; Alberts P; Sorensen AS
Eur J Clin Pharmacol; 2013 Mar; 69(3):459-65. PubMed ID: 22815050
[TBL] [Abstract][Full Text] [Related]
8. Effects of terbogrel on platelet function and prostaglandin endoperoxide transfer.
Muck S; Weber AA; Schrör K
Eur J Pharmacol; 1998 Feb; 344(1):45-8. PubMed ID: 9570446
[TBL] [Abstract][Full Text] [Related]
9. Production of platelet thromboxane A2 inactivates purified human platelet thromboxane synthase.
Hall ER; Tuan WM; Venton DL
Biochem J; 1986 Feb; 233(3):637-41. PubMed ID: 3707514
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation.
de Leval X; Benoit V; Delarge J; Julémont F; Masereel B; Pirotte B; Merville MP; David JL; Dogné JM
Prostaglandins Leukot Essent Fatty Acids; 2003 Jan; 68(1):55-9. PubMed ID: 12538091
[TBL] [Abstract][Full Text] [Related]
11. 1, 6-di-O-caffeoyl-β-D-glucopyranoside, a natural compound from Callicarpa nudiflora Hook impairs P2Y
Fu J; Zhu X; Wang W; Lu H; Zhang Z; Liu T; Xu H; Fu H; Ma S; Luo Y
Phytomedicine; 2017 Dec; 36():273-282. PubMed ID: 29157825
[TBL] [Abstract][Full Text] [Related]
12. Thromboxane synthase inhibitors and thromboxane A2 receptor antagonists: a quantitative structure activity relationships (QSARs) analysis.
Kontogiorgis C; Hadjipavlou-Litina D
Curr Med Chem; 2010; 17(28):3162-214. PubMed ID: 20666724
[TBL] [Abstract][Full Text] [Related]
13. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
14. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
[TBL] [Abstract][Full Text] [Related]
15. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Vercammen E; Freyne E; Janssen PA
Prog Clin Biol Res; 1989; 301():567-72. PubMed ID: 2529556
[No Abstract] [Full Text] [Related]
16. Pharmacological evaluation of both enantiomers of (R,S)-BM-591 as thromboxane A2 receptor antagonists and thromboxane synthase inhibitors.
Rolin S; Dogne JM; Vastersaegher C; Hanson J; Masereel B
Prostaglandins Other Lipid Mediat; 2004 Oct; 74(1-4):75-86. PubMed ID: 15560117
[TBL] [Abstract][Full Text] [Related]
17. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects.
Naran NH; Chetty N
Thromb Res; 1997 Dec; 88(5):399-407. PubMed ID: 9556227
[TBL] [Abstract][Full Text] [Related]
18. Thromboxane A Synthase: A New Target for the Treatment of Cardiovascular Diseases.
Mesitskaya DF; Syrkin AL; Aksenova MG; Zhang Y; Zamyatnin AA; Kopylov PY
Cardiovasc Hematol Agents Med Chem; 2018; 16(2):81-87. PubMed ID: 30039765
[TBL] [Abstract][Full Text] [Related]
19. The association of thromboxane A2 receptor with lipid rafts is a determinant for platelet functional responses.
Moscardó A; Vallés J; Latorre A; Santos MT
FEBS Lett; 2014 Aug; 588(17):3154-9. PubMed ID: 24996187
[TBL] [Abstract][Full Text] [Related]
20. Biosynthesis and pharmacological modulation of thromboxane in humans.
Patrono C
Circulation; 1990 Jan; 81(1 Suppl):I12-5; discussion I22-3. PubMed ID: 2136814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
